Editorial: Achieving Efficient Diabetes Care Through Understanding the Risk Factors, Markers, and Patient Experiences

Frontiers in Endocrinology, vol. 13, pp. 854167

Abstract

Achieving Efficient Diabetes Care Now Through Understanding the Risk Factors, Markers, and Patient's Experiences Until recently, the concept of a world without diabetes mellitus (DM) was not possible.This is now foreseeable with therapeutic advancements in technology in the form of our ability to create an artificial pancreas, stem cell transplant, personalized medicine of genomic-guided treatments, metabolic surgery, lifestyle interventions (1), and nutraceutical medicine (2).The greater challenges in delivering these therapies require adaptable healthcare systems, a trained healthcare workforce, and accessible and affordable treatments for those in greatest need of it.Bridging the gap between now and a better future for diabetes management requires a collective global effort that crosses international borders and boundaries, and the need for such a development is continuously pressing and supported by all organisations and governments.This begins by achieving an understanding of the increasing burden (3) and challenges of DM and its related complications when it comes to the healthcare systems, healthcare workers, and the person-level risk factors of DM.But this is also true for the markers of diseases related to DM, such as the life experiences of the people living with DM in coping and coming to terms with the disease in the form of a therapeutic relationship with professional careers and healthy living (4).The latter also requires local studies for more direct evidence and contexts (Al-Rifai et al., Sunny et al., Bukhsh et al. and de Jong et al.).In this special Frontiers in Endocrinology Research Topic, a number of articles examine this and the biological evidence of the maternal fasting plasma glucose profile in early pregnancy and its effect on foetal growth and birth outcomes (Guo et al.), preterm birth and birth weight, and the risk of type 1 diabetes (T1D) (Huang et al.), diabetes and sarcopenic obesity (Wang et al.), sodium-glucose cotransporter-2 inhibitors on liver enzyme (Euh et al.), and abnormalities in non-coding RNA as biomarkers (Chi et al.).This collective evidence takes us a step closer to the realisation of effective diabetes care for the prevention and normalisation of DM.Due to gestational diabetes mellitus (GDM), a new generation of human beings is set to be at higher risk of DM (Guo et al., Huang et al.).Women with GDM have almost a 10 times higher risk

Authors 4

1. Boon‐How Chew corresponding

   Universiti Putra Malaysia

   Affiliation as printed

   Clinical Research Unit, Hospital Pengajar Universiti Putra Malaysia (HPUPM Teaching Hospital), Persiaran MARDI - UPM, Serdang, Malaysia

   Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia

2. Rimke Cathelijne Vos Aachen Department Public Health and Primary Care/Leiden University Medical Center (LUMC)-Campus The Hague

   Leiden University Medical Center

   Affiliation as printed

   Department Public Health and Primary Care/Leiden University Medical Center (LUMC)-Campus The Hague, Leiden University Medical Center, Hague, Netherlands

3. Indah Suci Widyahening

   University of Indonesia

   Affiliation as printed

   Department of Community Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia

4. Kamlesh K. Khunti

   University of Leicester · Leicester General Hospital · National Institute for Health and Care Research

   Affiliation as printed

   Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, United Kingdom

   National Institute for Health Research Applied Research Collaboration-East Midlands, Leicester Diabetes Centre, Leicester, United Kingdom